Abstract
Gene expression profile (GEP) is a commercially available blood test which is noninferior to endomyocardial biopsy in detecting rejections after orthotopic heart transplant (OHT). A reference value below 34 in patients (pts) at least 6 months post OHT is associated with a very low risk of rejection. The variability of serial GEP scores has been shown to independently predict future hemodynamic compromise or death. The purpose of this study is to characterize the within pt GEP score variability in a large population over 4 periods of time post OHT.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
